Welcome to LookChem.com Sign In|Join Free

CAS

  • or

137863-17-3

N-[2’-(1H-tetrazol-5-yl)biphenyl-4-yl methyl]-N-Valeryl-(L)-Valine methyl ester, also known as Valsartan Methyl Ester, is a nonpeptide angiotensin II AT1-receptor antagonist. It is an analog of Valsartan (V095750) and is primarily used as an antihypertensive agent. N-[2’-(1H-tetrazol-5-yl)biphenyl-4-yl methyl]-N-Valeryl-(L)-Valine methyl ester is valuable in pharmaceutical secondary standards for quality control in pharmaceutical laboratories and manufacturing, offering a cost-effective alternative to in-house working standards.

137863-17-3 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 137863-17-3 Structure

  • Basic information

    1. Product Name: N-[2’-(1H-tetrazol-5-yl)biphenyl-4-yl methyl]-N-Valeryl-(L)-Valine methyl ester
    2. Synonyms: N-[2’-(1H-tetrazol-5-yl)biphenyl-4-yl methyl]-N-Valeryl-(L)-Valine methyl ester;L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, methyl ester;N-(1-Oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine methyl ester;Valsartan methyl ester;(S)-Methyl 2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoat;Valsartan Related CoMpound E;(S)-Methyl 2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)Methyl)pentanaMido)-3-Methylbutanoate;(S)-methyl 2-(N-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoate
    3. CAS NO:137863-17-3
    4. Molecular Formula: C25H31N5O3
    5. Molecular Weight: 449.54534
    6. EINECS: 1308068-626-2
    7. Product Categories: N/A
    8. Mol File: 137863-17-3.mol

  • Chemical Properties

    1. Melting Point: 129-130℃
    2. Boiling Point: 647.716 °C at 760 mmHg
    3. Flash Point: 345.526 °C
    4. Appearance: /
    5. Density: 1.169±0.06 g/cm3 (20 ºC 760 Torr)
    6. Refractive Index: N/A
    7. Storage Temp.: 2-8°C
    8. Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
    9. PKA: 4.15±0.10(Predicted)
    10. CAS DataBase Reference: N-[2’-(1H-tetrazol-5-yl)biphenyl-4-yl methyl]-N-Valeryl-(L)-Valine methyl ester(CAS DataBase Reference)
    11. NIST Chemistry Reference: N-[2’-(1H-tetrazol-5-yl)biphenyl-4-yl methyl]-N-Valeryl-(L)-Valine methyl ester(137863-17-3)
    12. EPA Substance Registry System: N-[2’-(1H-tetrazol-5-yl)biphenyl-4-yl methyl]-N-Valeryl-(L)-Valine methyl ester(137863-17-3)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 137863-17-3(Hazardous Substances Data)

137863-17-3 Usage

Uses

Used in Pharmaceutical Industry:
N-[2’-(1H-tetrazol-5-yl)biphenyl-4-yl methyl]-N-Valeryl-(L)-Valine methyl ester is used as a pharmaceutical compound for the treatment of hypertension. It functions as an antihypertensive agent by blocking the action of angiotensin II, a potent vasoconstrictor, thereby reducing blood pressure.
Used in Quality Control:
In the pharmaceutical industry, N-[2’-(1H-tetrazol-5-yl)biphenyl-4-yl methyl]-N-Valeryl-(L)-Valine methyl ester is used as a secondary standard in quality control. It provides a convenient and cost-effective alternative for the preparation of in-house working standards, ensuring the accuracy and reliability of pharmaceutical products.
Used in Research and Development:
N-[2’-(1H-tetrazol-5-yl)biphenyl-4-yl methyl]-N-Valeryl-(L)-Valine methyl ester is also utilized in research and development for the study of angiotensin II AT1-receptor antagonists and their potential applications in treating various cardiovascular conditions. It can be used to develop new drugs or improve existing ones, contributing to advancements in medical treatments.

Check Digit Verification of cas no

The CAS Registry Mumber 137863-17-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,7,8,6 and 3 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 137863-17:
(8*1)+(7*3)+(6*7)+(5*8)+(4*6)+(3*3)+(2*1)+(1*7)=153
153 % 10 = 3
So 137863-17-3 is a valid CAS Registry Number.

137863-17-3 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail

  • USP

  • (1708810)  Valsartan Related Compound E  United States Pharmacopeia (USP) Reference Standard

  • 137863-17-3

  • 1708810-15MG

  • 14,500.98CNY

  • Detail

137863-17-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name (S)-Methyl 2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoate

1.2 Other means of identification

Product number -
Other names methyl (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:137863-17-3 SDS

137863-17-3Relevant articles and documents

Convenient synthesis of Valsartan via a Suzuki reaction

Ghosh, Samir,Kumar, A. Sanjeev,Mehta

, p. 191 - 193 (2010)

An efficient synthesis of the angiotensin II inhibitor Valsartan (Diovan) is presented. The formation of the aryl-aryl bond represents the key step of its synthesis, which has been done by a Suzuki coupling of aryl boronate with 2-bromophenyl oxazoline with good yield and purity. This method overcomes many of the drawbacks associated with the previously reported syntheses.

Valsartan without genotoxic impurity and preparation method thereof (by machine translation)

-

Paragraph 0085-0088, (2020/05/09)

To, valsartan crude: is cyclised to obtain valsartan medoxomil (V), and the valsartan crude product (IV), is purified to obtain valsartan medoxomil (III), to obtain valsartan medoxomil (,) through hydrolysis pH, modulation (II), to obtain the valsartan crude product. pH. The valsartan crude product is obtained by cyclizing the valsartan medoxomil sodium, into salt to obtain valsartan medoxomil,and preparation method of the valsartan medoxomil prepared by the following steps N,N - refining to obtain valsartan medoxomil and, N,N -% of valsartan medoxomil. (by machine translation)

A facile synthesis of 5-(4'-substituted)-[1,1'-biphenyl]-2-yl)-1H-tetrazole: A key intermediate for synthesis of angiotensin II receptor antagonist

Reddy, Kesamreddy Ranga,Reddy, Emani Vijayabhaskar,Shanmukha Kumar

, p. 295 - 300 (2018/09/14)

A convenient commercial scale synthesis of 5-(4'-(substituted)-[1,1'-biphenyl]-2-yl)-1H-tetrazole 1 a common intermediate for so many angiotensin II receptors antagonists, has been achieved with high purity using a simple synthetic protocol. The advantage

A method for preparing methyl valsartan

-

, (2017/08/25)

The invention provides a preparation method of valsartan. The preparation method has the technical effects that amide methyl ester and sodium azide are used as raw materials and are catalyzed by amine salt to carry out tetrazole formation reaction; side effects are minimized by controlling the reaction course; main products are furthest generated; unreacted raw materials are recycled and reused; the yield in the preparation method is increased by more than 10% relative to the yields in existing processes; compared with the existing processes, the method has the effect that plenty of high-toxicity wastewater is no longer generated, and is easy to be widely popularized industrially.

DEPROTECTION METHOD FOR TETRAZOLE COMPOUND

-

, (2015/09/23)

The present invention relates to a method of deprotecting a tetrazole compound, useful as an intermediate for angiotensin II receptor blockers, and provides a novel production method of angiotensin II receptor blockers. Provided is a production method of a compound represented by the formula [3] or [4] or a salt thereof, including (i) reducing a compound represented by the formula [1] or [2] or a salt thereof in the presence of a metal catalyst and an alkaline earth metal salt, or (ii) reacting the compound with a particular amount of Br?nsted acid: wherein each symbol is as defined in the present specification.

AN IMPROVED PROCESS FOR THE PREPARATION OF N-PENTANOYL-N-[[2'-(1H-TETRAZOL-5-YI)[1,1'-BIPHENYL]-4-YI]METHYL]-L-VALINE

-

, (2012/05/19)

Disclosed herein is an improved process for the preparation of pure N-Pentanoyl-N-[[2'- (1h-Tetrazol-5-Y1)[1,1'-Biphenyl]-4-Yl]Methyl]-L-Valine employing highly active carbon.

Synthesis, pharmacokinetics, and pharmacodynamics studies of valsartan peptide derivatives

Wu, Chun,Hu, Yanpeng,Li, Qianbin,He, Limei,Chen, Jun,Cheng, Zeneng,Li, Yuanjian,Hu, Gaoyun

experimental part, p. 393 - 400 (2012/08/07)

In order to increase the intestinal permeability of valsartan, 14 esters and peptide derivatives of valsartan were chemically synthesized and their absorption characteristics were described. All derivatives were stable and could be better absorbed into th

IMPROVED PROCESS FOR PREPARING VALSARTAN

-

, (2011/10/31)

The invention relates to an improved process for the preparation of valsartan wherein the cycloaddition reaction is performed is an ether as reaction solvent, with a metal salt azide and in the present of zinc halides.

INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS

-

Page/Page column 30-31, (2010/11/30)

The present invention relates to novel substituted biphenyltetrazole compounds useful as intermediates in the preparation of angiotensin II antagonists, to a process for the synthesis of them and to a process for the conversion thereof to said molecules.

AN IMPROVED PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONIST

-

Page/Page column 10-11, (2008/06/13)

The present invention provides a method for the preparation of N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine (Valsartan) which comprises; treating N-[[2'-(1-triphenylmethyl-tetrazol-5-yl)biphenyl-4-yl]methy]-L-valine methy

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 137863-17-3